HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhang, L. Articles by Lefebvre, P. J. Search for Related Content PubMed PubMed Citation Articles by Zhang, L. Articles by Lefebvre, P. J. Social Bookmarking                What's this?

Risk of Developing Retinopathy in Diabetes Control and Complications Trial Type 1 Diabetic Patients With Good or Poor Metabolic Control

¹ Department of Biostatistics, University of Liège, Liège
² Department of Internal Medicine, Diabetology, University Hospital of Charleroi, Charleroi
³ Department of Medicine, Division of Diabetes, Nutrition and Metabolic Disorders, University Hospital of Liège, Liège, Belgium

OBJECTIVE—The study goal was to assess and predict the risk of developing retinopathy in type 1 diabetic patients with extreme metabolic control.

RESEARCH DESIGN AND METHODS—Based on material from the Diabetes Control and Complications Trial (DCCT) study (n = 1,441 patients), patients without retinopathy at baseline (DCCT primary cohort) were considered under good or poor metabolic control if the mean HbA_1c level (until the last visit) fell in the lower or upper 20% of the overall HbA_1c distribution, respectively. Retinopathy was recorded as either absent or present. Logistic regression was used to predict retinopathy from covariates used in the DCCT retinopathy study.

RESULTS—Among the 153 DCCT patients with "good metabolic control" (mean HbA_1c 6.87%), three-step change retinopathy developed in 15 (9.8%), and 138 (90%) remained free of retinopathy. Conversely, among the 166 patients with "poor metabolic control" (mean HbA_1c 9.49%), the complication did not develop in 71 (43%) and did develop in 95 (57%). Whereas occurrence of diabetic retinopathy was primarily due to metabolic control (P < 0.0001) and duration of participation in the study (P < 0.0001), two other covariates were found to be significant prognostic factors of the complication: HbA_1c at baseline (OR 1.37, P < 0.001) and BMI (OR 1.11, P < 0.05).

CONCLUSIONS—This study confirms that retinopathy develops in 10% of patients with type 1 diabetes under good metabolic control, whereas >40% of patients with type 1 diabetes remain free of retinopathy despite poor metabolic control. After adjusting for metabolic control and duration of participation in the study, it was found that previous glycemic exposure (HbA_1c) and BMI may provide a possible explanation to such paradoxical clinical situations.

Abbreviations: AIC, Akaike’s Information Criterion • DCCT, Diabetes Control and Complications Trial • ETDRS, Early Treatment Diabetic Retinopathy Study • SNPDR, severe nonproliferative diabetic retinopathy

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				X. Liu, M. G. Mameza, Y. S. Lee, C. I. Eseonu, C.-R. Yu, J. J. Kang Derwent, and C. E. Egwuagu Suppressors of Cytokine-Signaling Proteins Induce Insulin Resistance in the Retina and Promote Survival of Retinal Cells Diabetes, June 1, 2008; 57(6): 1651 - 1658. [Abstract] [Full Text] [PDF]

				J. S. Ng, M. A. Bearse Jr, M. E. Schneck, S. Barez, and A. J. Adams Local Diabetic Retinopathy Prediction by Multifocal ERG Delays over 3 Years Invest. Ophthalmol. Vis. Sci., April 1, 2008; 49(4): 1622 - 1628. [Abstract] [Full Text] [PDF]

				R Kawasaki, J M Tielsch, J J Wang, T Y Wong, P Mitchell, Y Tano, M Tominaga, T Oizumi, M Daimon, T Kato, et al. The metabolic syndrome and retinal microvascular signs in a Japanese population: the Funagata study Br. J. Ophthalmol., February 1, 2008; 92(2): 161 - 166. [Abstract] [Full Text] [PDF]

				D. A. Antonetti, A. J. Barber, S. K. Bronson, W. M. Freeman, T. W. Gardner, L. S. Jefferson, M. Kester, S. R. Kimball, J. K. Krady, K. F. LaNoue, et al. Diabetic Retinopathy: Seeing Beyond Glucose-Induced Microvascular Disease Diabetes, September 1, 2006; 55(9): 2401 - 2411. [Abstract] [Full Text] [PDF]

				C. E.M. De Block, I. H. De Leeuw, and L. F. Van Gaal Impact of Overweight on Chronic Microvascular Complications in Type 1 Diabetic Patients Diabetes Care, July 1, 2005; 28(7): 1649 - 1655. [Abstract] [Full Text] [PDF]

				The DIRECT Programme Study Group The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics Journal of Renin-Angiotensin-Aldosterone System, March 1, 2005; 6(1): 25 - 32. [Abstract] [PDF]

				S. Hadjadj, F. Pean, Y. Gallois, P. Passa, R. Aubert, L. Weekers, V. Rigalleau, B. Bauduceau, A. Bekherraz, R. Roussel, et al. Different Patterns of Insulin Resistance in Relatives of Type 1 Diabetic Patients With Retinopathy or Nephropathy: The Genesis France-Belgium Study Diabetes Care, November 1, 2004; 27(11): 2661 - 2668. [Abstract] [Full Text] [PDF]

				A. Parvanova, I. Iliev, M. Filipponi, B. D. Dimitrov, M. Vedovato, A. Tiengo, R. Trevisan, G. Remuzzi, and P. Ruggenenti Insulin Resistance and Proliferative Retinopathy: A Cross-Sectional, Case-Control Study in 115 Patients with Type 2 Diabetes J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4371 - 4376. [Abstract] [Full Text] [PDF]

				L Kessel, B Sander, P Dalgaard, and M Larsen Lens fluorescence and metabolic control in type 1 diabetic patients: a 14 year follow up study Br. J. Ophthalmol., September 1, 2004; 88(9): 1169 - 1172. [Abstract] [Full Text] [PDF]

				R. S.A. Shinkai, J. P. Hatch, J. E. Cornell, and C.-K. Yeh Intraoral Tactile Sensitivity in Adults With Diabetes Diabetes Care, April 1, 2004; 27(4): 869 - 873. [Abstract] [Full Text] [PDF]

				R Donnelly, I Idris, and J V Forrester Protein kinase C inhibition and diabetic retinopathy: a shot in the dark at translational research Br. J. Ophthalmol., January 1, 2004; 88(1): 145 - 151. [Abstract] [Full Text] [PDF]

				M. Henricsson, L. Nystrom, G. Blohme, J. Ostman, C. Kullberg, M. Svensson, A. Scholin, H. J. Arnqvist, E. Bjork, J. Bolinder, et al. The Incidence of Retinopathy 10 Years After Diagnosis in Young Adult People With Diabetes: Results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS) Diabetes Care, February 1, 2003; 26(2): 349 - 354. [Abstract] [Full Text] [PDF]

				H. A. van Leiden, J. M. Dekker, A. C. Moll, G. Nijpels, R. J. Heine, L. M. Bouter, C. D. A. Stehouwer, and B. C. P. Polak Risk Factors for Incident Retinopathy in a Diabetic and Nondiabetic Population: The Hoorn Study Arch Ophthalmol, February 1, 2003; 121(2): 245 - 251. [Abstract] [Full Text] [PDF]

				H. Dorchy, C. Claes, and C. Verougstraete Risk Factors of Developing Proliferative Retinopathy in Type 1 Diabetic Patients : Role of BMI Diabetes Care, April 1, 2002; 25(4): 798 - 799. [Full Text]